2 Dec 2019
Lewis Cameron Appointed as Chief Operating Officer

Lewis Cameron, Former Head of Global Clinical Development at Covance, Appointed as Chief Operating Officer

 

Guildford, UK2 December 2019: Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, today announces the appointment of Lewis Cameron as Chief Operating Officer (COO) and to the Board, effective from January 20th, 2020.

Lewis is an experienced senior executive with a proven track record in the global pharmaceutical services sector, including oncology expertise, and significant M&A experience. He was the Head of Global Clinical Development at Covance, the CRO division of Laboratory Corporation Holdings of America (LabCorp), from 2017 to 2019, where as an integral part of the senior management team, they achieved $4.3 billion of revenues in 2018. Prior to that, he was the Executive Vice President of Oncology and the General Manager for CEE and APAC Regions at Chiltern International from 2014 to 2017, where he was instrumental in driving the integration of a number of acquired businesses, had oversight of the client portfolio in multiple therapeutic areas, and led the growth and development of the clinical business.

Lewis also brings experience from the client side of the pharmaceutical services sector, having been Chief Executive Officer (CEO) of a biotech business, Avillion LLP, from 2012 to 2014 where, following the venture capital seed financing of the company, he signed a significant in-licensing deal with Pfizer for the further development of the company’s innovative cancer therapies. Prior to that, Lewis was CEO of Clearstone Central Laboratories, a global central lab organisation based in Paris, France, from January 2010 to July 2011, where he achieved an operational and financial turnaround resulting in its successful acquisition by LabCorp.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: “We are delighted to further strengthen our management team with Lewis’s appointment. He will take on operational responsibility across our whole business and I have no doubt we will benefit from his considerable operational expertise, M&A experience and proven track record of growth across the pharmaceutical services sector as we deliver on our strategy.”

Lewis Cameron said: “Ergomed has a highly differentiated offering in the clinical services marketplace and I believe there are significant opportunities to build further on the company’s growth trajectory. I look forward to working closely with the CRO and PV leadership teams and with the commercial and sales teams across the business to continue to build the Company’s leadership position as an integrated specialized mid-tier pharmaceutical services company.”

Save as disclosed below, in relation to current directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Lewis Cameron’s appointment.

 

Mr Lewis Cameron, aged 56, currently holds the following directorships:

  • Elm Grove Property Management Company Limited
  • Bond Biomedical Services Limited

 

 

Enquiries:

Ergomed plc  Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Sue Stuart ergomed@consilium-comms.com
Matthew Neal / Olivia Manser
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: https://ergomedplc.com.